COVID-19 vaccine ng Pfizer, BioNTech lumabas na 95 porsyentong epektibo
Inanunsiyo ng Pfizer at BioNTech ang magandang resulta ng kanilang experimental vaccine laban sa Coronavirus Disease o COVID-19.
Sa abiso ng dalawang kumpanya sa araw ng Miyerkules, November 18, lumabas sa final efficacy analysis sa phase 3 study na 95 porsyentong epektibo ang kanilang bakuna.
Wala anilang naging seryosong banta sa kalusugan ng mga sumailalim sa two-dose vaccine.
Dahil dito, mag-a-apply ang kumpanya ng emergency use authorization sa US regulators sa mga susunod na araw.
Ayon kay Dr. Albert Bourla, chairman at CEO ng Pfizer, ikinokonsidera ito bilang isang mahalagang hakbang sa loob ng walong buwang pagbubuo ng bakuna para malagpasan ang nararanasang pandemya.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” pahayag nito.
“With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” dagdag pa ni Bourla.
Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.